Speakers

Expand/Collapse

James Nagarajah
Assistant Professor
Radboud University Medical Centre (Radboudumc), The Netherlands Department of Radiology and Nuclear Medicine

Prof. Dr. med. James Nagarajah’s career as nuclear physician has led him via the Clinic for Nuclear Medicine of the UMC Essen (Germany) and the Memorial Sloan Kettering Cancer Center (USA) to Radboud University Medical Centre (Radboudumc) in The Netherlands, where he is Assistant Professor at the Department of Radiology and Nuclear Medicine. At Radboudumc James is involved with research & development of new radiopharmaceuticals applying radionuclides like lutetium-177 and lead-212. Prof. Nagarajah is member of FIELD-LAB’s Medical Advisory Board.

Day Two

Thursday 10th December 2020

10:40 am | Nuclear Medicine Innovation: Synergy of competences

Thomas Reiner
Associate Member
Department of Radiology Chemical Biology Program Memorial Sloan Kettering Cancer Center

Day Two

Thursday 10th December 2020

3:15 pm | PARP Targeted Auger Electrons: Nanometre Scale Radiotherapy

Laurent Tanguy
Microfluidics Expert iMiLAB
PMB - Alcen

Day One

Wednesday 9th December 2020

3:30 pm | Microfluidic Production of Radiopharmaceuticals

Franck Denat
Co Founder
Chematech

Day One

Wednesday 9th December 2020

2:20 pm | Development of theranostics from Preclinical to Clinical Phase I

Chris Rundfelt
Professor of Pharmacology and Toxicology (APL)
University of Veterinary Medicine Hannover

Day One

Wednesday 9th December 2020

2:20 pm | Development of theranostics from Preclinical to Clinical Phase I

Eftychia Koumarianou
Director Pre-Clinical & Pharmacy
ABX - CRO advanced pharmaceutical services

Day One

Wednesday 9th December 2020

2:20 pm | Development of theranostics from Preclinical to Clinical Phase I

1:40 pm | It takes 2 to Tango: Path from Preclinical to Clinical Phase I for Imaging and Therapeutic Radiopharmaceuticals

Andreas Kluge
Medical Director
ABX - CRO advanced pharmaceutical services

Day One

Wednesday 9th December 2020

2:20 pm | Development of theranostics from Preclinical to Clinical Phase I

Jens Kaufmann
Managing Director
1717 Life Science Ventures

 

Day Two

Thursday 10th December 2020

1:00 pm | Panel Discussion: Opening Up About Funding Challenges in Radiopharmaceuticals

12:40 pm | Le Chatelier – Don’t Leave Anyone Behind During Radiopharmaceutical Development

Dale Ludwig
Chief Science & Technology Officer
Actinium Pharmaceuticals

Day Two

Thursday 10th December 2020

2:30 pm | Panel Discussion: Beyond PSMA – How Do We Realistically Identify New Targets to Take on with Radioligand Therapy

Chris Leamon
Indiana Site Head, Vice President of Discovery Research
Advanced Accelerator Applications

Day Two

Thursday 10th December 2020

2:30 pm | Panel Discussion: Beyond PSMA – How Do We Realistically Identify New Targets to Take on with Radioligand Therapy

Maurizio Mariani
Head of Research & Development
Advanced Accelerator Applications

Day One

Wednesday 9th December 2020

11:50 am | Combining Radionuclides with a Comprehensive Array of Therapeutics for Improved Therapeutic Efficacy

Alison Armour
Founder
Curadh Pharmaceuticals

Tom Christian Holm Anderson
PI 180 ºN, the Norwegian Nuclear Medicine Consortium Chief Radiochemist & Production Manager Centre for Nuclear Medicine & PET Department of Radiology
Haukeland University Hospital

 

Joao Osso
Section Head
International Atomic Energy Authority (IAEA)

Day Two

Thursday 10th December 2020

12:15 pm | Current Radioisotope Stockpiles & Sourcing/Production Methods

Julian Kelly
Founder & Executive Director
Isoclide Medical

Day Two

Thursday 10th December 2020

10:00 am | 100% Assured Supply — 212Pb from Simple Generators Based on a Naturally-occuring Parent (228Th)

George Sgouros
Director, Radiological Physics Division, Professor of Radiology & Radiological Science
Johns Hopkins Medicine

Alberto Andrighetto

Istituto Nazionale di Fisica Nucleare

Day Two

Thursday 10th December 2020

10:20 am | The ISOLPHARM Project: New Production Method of High Specific Activity Beta-emitting Radionuclides

Cyril Berthet
Pharmaco-Imaging Unit Director
Oncodesign

Day One

Wednesday 9th December 2020

2:20 pm | Development of theranostics from Preclinical to Clinical Phase I

1:40 pm | It takes 2 to Tango: Path from Preclinical to Clinical Phase I for Imaging and Therapeutic Radiopharmaceuticals

Jason Hurt
Chief Medical Officer
Orano Med

Day One

Wednesday 9th December 2020

12:10 pm | Radiopharmaceuticals & Clinical Oncology Trials

Izabela Tworowska
Chief Scientific Officer
RadioMedix Inc

Day Two

Thursday 10th December 2020

3:35 pm | Progress in Targeted Alpha-particle Therapies – Our Clinical Experience & Regulatory Perspective

Chris Behrenbruch
CEO
Telix Pharmaceuticals

Day One

Wednesday 9th December 2020

10:00 am | Bringing Radiopharmaceuticals to Mainstream Oncology – The “Combo”

Greg Mullen
Chief Executive Officer
Theragnostics

Day Two

Thursday 10th December 2020

1:00 pm | Panel Discussion: Opening Up About Funding Challenges in Radiopharmaceuticals

Oliver Sartor
Professor of Medicine Medical Director
Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research

Day One

Wednesday 9th December 2020

4:10 pm | Lessons Learned From Radiopharmaceutical Trials in Prostate Cancer

Roland Turck
Managing Partner
TurckBio International Consulting

Day One

Wednesday 9th December 2020

3:45 pm | Radiopharmaceuticals – A Story of Success & Failure

Linjing Mu
Investigator
ETH Zürich

Day One

Wednesday 9th December 2020

2:20 pm | Development of theranostics from Preclinical to Clinical Phase I

2:00 pm | Optimising Preclinical Testing For Fast Translation To The Clinic

Markus Luster
Chair of the Department of Nuclear Medicine
University Hospital Marburg

Day One

Wednesday 9th December 2020

11:30 am | Novel Concepts in Radionuclide Therapy of Neuroendocrine Tumours

Rune Sundset
Director Of The Pre- Clinical Unit
University of Tromsø - The Arctic University of Norway (UiT)

Markus Luster

Chair of the Department of Nuclear Medicine

University Hospital Marburg

To find out more information on this year's event, including what topics these speakers will be discussing:

To find out more information on this year's event, including what topics these speakers will be discussing: